They are working with entrepreneurs to turn breakthrough science into breakthrough medicine. Abingworth follows a multipronged strategy with investments at all stages of product development across multiple disease areas, including biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, and specialty pharma. They aim to foster the creation of important new treatments for patients.